ArticleHealth science reports2026
The Value of the ALBI and ALBI-PLT Scores in Predicting Esophageal Varices in Cirrhotic Patients: A Cross-Sectional Study.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Esophageal varices (EVs) are a common and life-threatening complication of liver cirrhosis. Endoscopic screening is recommended but remains invasive and resource-intensive. This study aimed to evaluate the diagnostic performance of the albumin-bilirubin (ALBI) and ALBI-platelet (ALBI-PLT) scores for predicting the presence of esophageal varices in cirrhotic patients. Methods: This cross-sectional study included 152 patients with liver cirrhosis who underwent screening endoscopy at Cho Ray Hospital between November 2022 and May 2023. ALBI and ALBI-PLT scores were calculated from routine laboratory parameters. Receiver operating characteristic (ROC) analysis was performed to evaluate diagnostic performance. Results: Among 152 cirrhotic patients (mean age 56 years, 65.8% male), the prevalence of EVs was 56%. The ALBI score showed moderate predictive performance for EVs (AUC 0.78; 95% CI 0.70-0.84) and varices needing treatment (AUC 0.79). The ALBI-PLT score demonstrated similar performance (AUC 0.76 and 0.77, respectively). Using a cutoff of ALBI > -2.76, 20.4% of patients could potentially avoid screening endoscopy, with 9.7% of varices needing treatment missed. Conclusion: ALBI and ALBI-PLT scores may serve as simple non-invasive triage tools to identify low-risk cirrhotic patients who may safely defer screening endoscopy, particularly in resource-limited settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.